A serious impediment to gene and protein replacement therapy in hemophilia A is the development of inhibitors. Mechanisms responsible for inhibitor development include T-cell-dependent adaptive immune responses and the CD28-B7 signaling pathway that eventually leads to the formation of antibodies directed against factor VIII (FVIII). Indoleamine 2,3-dioxygenase (IDO) is a potent immunosuppressive enzyme that can inhibit T-cell responses and induce T-cell apoptosis by regulation of tryptophan metabolism. Kynurenine, one of the metabolites of tryptophan, has been implicated as an immune modulator. Here we hypothesize that co-delivery of the genes for FVIII and IDO can attenuate inhibitor formation. Using transposon-based gene delivery, we observed long-term therapeutic FVIII expression and significantly reduced inhibitor titers when the genes were codelivered. Co-expression of FVIII and IDO in the liver was associated with increased plasma kynurenine levels, an inhibition of T-cell infiltration and increased apoptosis of T cells within the liver. These experiments suggest that modulation of tryptophan catabolism through IDO expression provides a novel strategy to reduce inhibitor development in hemophilia gene/protein therapy.
Introduction
Genetic-based approaches toward the treatment of hemophilia A have enormous potential as only modest elevations in factor VIII (FVIII) levels can produce a therapeutic benefit. Furthermore, different target organs can be harnessed to produce and secrete functionally active FVIII including hepatocytes, 1,2 endothelial cells 3 and muscle cells 4, 5 providing numerous approaches for gene delivery. Despite these advantages, successful FVIII replacement has been complicated by the development of inhibitory antibodies to various epitopes of the FVIII molecule. Inhibitor development occurs in B30-50% of patients receiving protein replacement therapy, 6, 7 and in over 80% of animals receiving gene therapy. 3, [8] [9] [10] [11] [12] FVIII inhibitors rapidly inactivate FVIII and dramatically decrease the efficacy of treatment; therefore approaches to eliminate the formation of inhibitors are of significant interest to scientists and clinicians treating hemophilia.
Primary prevention of inhibitor development is not used clinically, but has been applied to experimental models and requires the use of potent immunosuppressive drugs, such as cyclophosphamide, which have significant side effects. Immune tolerance by constant exposure to large amounts of FVIII protein is used both clinically and experimentally, but is extremely expensive and not always effective. 6 Neonatal gene therapy is an alternative approach to induce tolerance as naive immune systems are less likely to produce inhibitors, 3, 13 but the risks associated with neonatal gene transfer may not be worth the potential benefits. Therefore, new approaches to modulate inhibitor development warrant investigation.
The exact mechanisms that regulate inhibitor development remain unclear, however evidence indicates the process is T-cell dependent and requires the CD28 signaling pathway. [14] [15] [16] [17] [18] The protein B7, which is expressed on the surface of antigen-presenting cells, interacts with CD28 expressed on T cells, thereby activating T-cell proliferation and promoting the humoral response to FVIII. 14, 17 Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a second high-affinity T-cell receptor for the B7 ligand, and is a negative regulatory of T-cell activation. [19] [20] [21] The soluble fusion protein CTLA-4-immunoglobulin (CTLA-4-Ig) can block CD28-B7 interactions in vivo and prevent T-cell-dependent responses in many animal models of autoimmunity and transplantation. 19, 22 Furthermore, administration of CTLA-4-Ig can inhibit the secondary immune response to FVIII in mice that have already developed relatively high-titer anti-FVIII antibodies.
14 Recent research indicates that the immunosuppressive effects of CTLA-4-Ig work by regulating tryptophan catabolism. 23, 24 CTLA-4-Ig interferes with the interaction between CD28 and B7, leading to the activation of downstream cellular events and the production of interferon-g (IFN-g). IFN-g has been shown to upregulate the transcription of the gene encoding indoleamine 2,3-dioxygenase (IDO), which is involved in tryptophan catabolism by catalyzing the oxidative cleavage of the indole ring. 25 Derivatives of tryptophan catabolism, especially kynurenines, have been shown to have immune regulatory properties, and can induce T-cell apoptosis through processes mediated by oxygen radicals. 23, 24 Another theory suggests that local depletion of tryptophan in the microenvironment leads to inhibition of T-cell proliferation and nonspecific immunosuppression. 26 Cells transfected or transduced to overexpress IDO acquire the ability to inhibit T-cell proliferation in vitro and to suppress T-cell responses to cell and tissue allografts in vivo. [27] [28] [29] On the basis of these observations, we hypothesized that co-delivery of the FVIII and IDO genes would prevent FVIII inhibitor development and may prevent the destruction of FVIII-expressing cells leading to an enhanced therapeutic response.
In this study, Sleeping Beauty transposons harboring the IDO and FVIII genes were co-administered by hydrodynamic injection to adult hemophilia A mice. We observed that co-transfer of IDO-and FVIII-expressing transposons with a hyperactive transposase led to a significant reduction in inhibitor development, and provided increased FVIII levels with phenotypic correction of the disorder. Mechanistic investigations revealed that reduced inhibitor formation correlated with higher plasma kynurenine concentrations. Furthermore, within liver tissue from gene-treated animals, a reduction in T-cell infiltration/proliferation and an increase in T-cell apoptosis were observed. These findings indicate that modulation of the tryptophan catabolism pathway can attenuate inhibitor formation in a gene therapy model of hemophilia A.
Results

Co-expression of FVIII and IDO in vivo
Transposons expressing human B-domain-depleted FVIII and human IDO have been described previously ( Figure 1a ) and their ability to express biologically active proteins has been confirmed in vitro. 3, 30 To verify co-gene delivery of FVIII and IDO can effectively express both proteins in vivo, hemophilia mice received a hydrodynamic injection containing equal amounts of the transposons pMSZ-CMV-FVIII and pMSZ-CMV-IDO (100 mg each), and 20 mg of transposase plasmid. Animals were killed 3 days or 4 weeks after gene delivery and transgene expression from liver tissue was analyzed by western blotting. Robust FVIII and IDO protein expression was observed 3 days after gene delivery and reduced but still persistent protein was observed at the 28-day time point (Figure 1b) . A reduction in protein expression between the peak at day 3 and day 28 is routinely seen following transposon-based gene delivery. 31 These results suggest that co-gene delivery is able to achieve adequate expression of both therapeutic proteins for an extended period of time.
Co-delivery of IDO attenuates inhibitor development
Given that co-delivery of the genes for FVIII and IDO was able to achieve significant levels of protein expression, we attempted to determine if varying the amount of the IDO transposon would influence inhibitor development toward FVIII. Hemophilia mice were injected with the FVIII transposon (pMSZ-CMV-FVIII) plus the transposase (pCMV-HSB16) with or without varying amounts of the IDO transposon (pMSZ-CMV-IDO). The empty plasmid pcDNA3.1 served as filler DNA to keep the total amount of delivered DNA constant. On the basis of several preliminary experiments (data not shown), we found that a 1:1 ratio of the pMSZ-CMV-FVIII/pMSZ-CMV-IDO (100:100 mg) and 10:1 ratio of transposon/ transposase gave the highest level of long-term FVIII expression. To analyze the presence of inhibitors, blood samples were collected at days +3, 7, 14 and 28 and every 4 weeks thereafter until the end of the experiment (24 weeks or 168 days). Plasma samples were analyzed for FVIII activity and inhibitor titers as previously described. At 2 weeks after gene delivery, FVIII activity levels fell to about 20% of normal, down from B100% observed on day +3. For animals that received FVIII plus IDO Hemophilia A mice received the plasmids in a by hydrodynamic injection. Animals were killed at 3 and 28 days after gene delivery. Liver samples were separated by electrophoresis and probed with antibodies to FVIII and IDO. Robust protein expression was observed at day +3 for both proteins, whereas reduced but still significant protein expression was observed at 28 days.
IDO modulates inhibitor formation L Liu et al transposons (group 1), FVIII levels remained stable at B7-15% from the 4-week time point onward, whereas FVIII levels continued to fall to baseline levels by day 56 in animals that received the FVIII transposon alone (group 2) (Figure 2a ). FVIII inhibitors were detected by 1 week and reached a peak by 4 weeks after gene delivery in both the groups (Figure 2b ). However, animals that had received the FVIII+IDO transposons had significantly lower peak inhibitory titers (B1.8 Bethesda units, BU) compared to animals that received the FVIII transposon alone (B6.5 BU). The observed inhibitor titers and FVIII activities are similar to that observed by Ohlfest et al., 12 following hydrodynamic administration of FVIII transposons. Inhibitor titers remained low in animals that received the IDO transposon (B1.4 BU), whereas they remained high (B5.5 BU) throughout the remainder of the experiment for animals receiving only the FVIII transposon ( Figure 2b ).
Plasma kynurenine concentrations (Kyn) were measured in each group and in control animals that received no treatment. There was a small, yet significant increase in Kyn levels in animals receiving the IDO transposon at day +3 and weeks 2, 8 and 16, compared to Kyn levels in animals from the group receiving the FVIII transposon alone or in control untreated mice ( Figure 2c ). This difference was lost by the termination of the experiment. Western blotting of liver tissue at the termination of the experiment was able to detect FVIII and IDO protein expression in animals that received the FVIII+ IDO transposons (group 1), but was unable to detect any FVIII or IDO protein in animals from the FVIII transposon alone (group 2) or untreated mice ( Figure 3a) . The presence of FVIII and IDO protein expression in group 1 was confirmed by immunohistochemistry ( Figure 3b ). FVIII-and IDO-expressing hepatocytes were detected in group 1 whereas no FVIII or IDO expression could be detected in hepatocytes from animals in group 2 or untreated mice. Long-term transgene expression following Sleeping Beauty-mediated gene delivery has been attributed to gene integration. Insertion site analysis using the splinkerette PCR technique confirmed molecular evidence of integration (data not shown).
IDO expression modifies T-cell responsiveness and increases apoptosis
With the finding that co-gene therapy can reduce FVIII inhibitor development, we sought to elucidate the mechanism of immune modulation. Earlier research has suggested that the immune-modulatory effects of IDO are due to two processes. One mechanism may be the depletion of the essential amino acid (tryptophan) in microenvironment that inhibits T-cell proliferation. The second mechanism, which is not mutually exclusive, is the induction of apoptosis in lymphocytes by metabolites of tryptophan degradation, mainly N-formyl-kynurenine. In our previous studies, we verified that overexpression of IDO within lung allografts can inhibit local T-cell responses. In the present study, we observe a similar process of diminished T-cell responsiveness. There was a significant reduction in the number of CD3 + T cells found infiltrating the liver 2 weeks after gene therapy in animals receiving the FVIII+IDO transposons compared to the group receiving the FVIII transposon alone (Po0.001) (Figures 4a and c) . This suggests that local IDO expression can inhibit T-cell responsiveness (infiltration and/or proliferation) following exposure to the protein antigen (FVIII) Figure 2 Long-term factor VIII (FVIII) activity, inhibitor titers and kynurenine concentrations in gene-treated hemophilia mice. (a) Adult hemophilia A mice (6-to 7-week old, n ¼ 5 per group per time point) received plasmid DNA by hydrodynamic injection. The FVIII+IDO group (') received both transposons plus active transposase, whereas the FVIII alone group (m) received the FVIII transposon, active transposase and a filler plasmid in place of the indoleamine 2,3-dioxygenase (IDO) transposon. Plasma samples were collected at various times after gene delivery and FVIII activity assays were performed using the Coatest. (b) FVIII inhibitor titers were measured by a Bethesda assay. (c) Plasma kynurenine (Kyn) concentrations in control and gene-treated animals were determined at several time points. In all graphs the mean ± the standard error of measurement (s.e.m.) is charted.
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produced by the gene therapy. In addition, we observed that overexpression of IDO was able to induce T-cell apoptosis within the liver (Figures 4b and d ). These observations suggest that the inhibitory effects of IDO may be due to the combination of inhibiting lymphocyte infiltration and proliferation, and promoting lymphocyte apoptosis. The in vivo observation of increased apoptosis was verified by in vitro co-culture studies. Isolated peripheral blood mononuclear cells (PBMCs) from hemophilia A mice were co-cultured with murine heart endothelial cells (SMHEC) overexpressing IDO or green fluorescent protein (GFP) as a control. The incubated cells were stimulated by phytohemagglutinin (PHA) to promote T-cell activation and proliferation. Flow cytometry was performed 24 h after co-incubation to detect apoptosis. The results indicated that co-culture with SMHECexpressing IDO caused approximately 80% of the cells to undergo apoptosis (Figures 5a(3) and b) . This effect was blocked by the IDO inhibitor 1-MT (Figures 5a(4) and b, Po0.001), reaching the control level of apoptosis at B10% (Figures 5a(1) and b) . We further investigated the function of the major metabolite of tryptophan degradation, kynurenine. Kynurenine was added to the culture medium of control SMHEC to reach the same concentration as that produced by the IDO-expressing cells (0.45 mM). PBMCs incubated under this condition underwent apoptosis (B55%, Figures 5a(2) and b) at a lower rate than that observed when incubated with IDOexpressing SMHEC (B80%). These results suggest that kynurenine is not the only metabolite responsible for the induction of PBMCs apoptosis, although it is responsible for the majority of the effect (Figures 5a and b) .
Discussion
Clinical management of patients with FVIII inhibitors is challenging as treatment options are limited. Immunosuppressive agents such as cyclophosphamide or immune tolerance by exposure of the patient to high doses of FVIII concentrates have potential risks, are not always effective and can be extremely expensive (exceeding US$1 000 000). 6 New modalities that modulate or prevent the development of inhibitors are therefore of substantial interest. Several laboratories have investigated different protocols to prevent inhibitor formation in hemophilia. Induction of immune tolerance has been achieved using the following approaches: mucosal (nasal or oral) antigen administration, 32 transient blockade of the inducible co-stimulator pathway by an anti-ICOS monoclonal antibody, 33 hematopoietic stem cell gene IDO modulates inhibitor formation L Liu et al therapy following low-toxicity pretransplantation conditioning and targeted immunosuppression, 34 hepatic gene transfer of naked DNA with transient immunosuppression, 35 hepatic transfer with viral vectors of FIX, 36 or the transient administration of a multidrug cocktail consisting of a specific peptide antigen, an immune suppressive drug (rapamycin) and the cytokine (interleukin 10, IL-10) (R Herzog, personal communication). Each of these approaches involves slightly different mechanisms of immune modulation and may be dependent on the route of antigen administration. For mucosal (nasal or oral) tolerance, immune modulation is characterized by the induction of Th2 and Th3 cells that secret large amounts of the suppressive cytokines IL-10 and transforming growth factor-b on antigen restimulation. 32 In viral hepatic gene transfer, immune tolerance to FIX is thought to be due to the induction of antigenspecific T-regulatory cells (CD4 + CD25 + T regs ), which are capable of suppressing cytotoxic T lymphocytes and antibody responses to the transgene product. À T cells that mount the immune response.
38,39
The multidrug cocktail approach is also believed to provide tolerance by deletion of CD4 + T cells and induction of CD4 + CD25 + T regs . In the present study, IDO overexpression is used to induce immune suppression to FVIII. As mentioned previously, inhibitor development is a CD4 + T helper cell-dependent process. Theoretically, local inhibition of CD4 + T-cell infiltration/proliferation or induction of apoptosis of activated T cells responding to the antigen could minimize the immune response. IDO is an enzyme that catalyzes the oxidative cleavage of the indole ring of tryptophan, an essential amino acid. 40 Studies have demonstrated that increased tryptophan catabolism by IDO leads to the suppression of T-cell proliferation and induces apoptosis of activated T cells. 23, 41 On the basis of these observation, we hypothesized that co-gene therapy of IDO with FVIII may prevent inhibitor development in hemophilia mice. Our results verify this hypothesis. Mice receiving co-gene delivery of human IDO and FVIII had lower inhibitor titers than the mice receiving the FVIII gene alone, although IDO was not able to eliminate the immune response completely. 
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The mechanism of attenuated inhibitor development in the present study is distinct from the other approaches described using immunosuppressive cytokines or T regs . Here, inhibition of T-cell activation by preventing T-cell infiltration/proliferation and induction of T-cell apoptosis are the major mechanisms. This was confirmed by the reduction of T-cell infiltration and increased T-cell apoptosis within liver tissue from mice receiving co-gene delivery. The in vitro observations were also consistent with the in vivo findings, specifically IDO expression was able to induce apoptosis of PHA-stimulated PBMCs. These findings that immune 
tolerance with IDO is dependent on T-cell apoptosis are consistent with the observations of Wells et al., 42 where they found that T-cell apoptosis was required in the induction of tolerance following cardiac transplantation. On the basis of these observations, we propose that the immune modulation caused by IDO overexpression is a localized state of general immunosuppression. Blockade of T-cell proliferation and T-cell apoptosis leads to subsequent dampening of the humoral responses to FVIII. Most literature supports this view, however there have been reports of IDO overexpression causing modulation of T regs populations in other model systems. 43 Because we did not perform in vivo analysis of CD4 + CD25
+ T regs populations, we cannot exclude the possibility that some of the immune tolerance observed is the result of upregulation of these populations. Furthermore, it has been observed that viral gene delivery of FIX through the hepatic route can induce CD4 + CD25
+ T regs population. 36, 37 However, with our hepatic hydrodynamic approach using FVIII, all of our control animals elicited robust immune responses to the introduced FVIII gene suggesting that IDO and not the route of gene administration was responsible for the immune modulation observed.
This study also reveals that one of the metabolites of tryptophan catabolism, kynurenine, has the ability to induce apoptosis almost as efficiently as IDO expression itself. When kynurenine was added to the culture medium of control cells at a concentration identical to the level achieved in IDO-expressing cells, significant apoptosis of PBMCs was observed (B55%). This finding raises the possibility that small molecule analogues of kynurenine or kynurenine itself could be used to prevent inhibitor development or be used in other scenarios where immune modulation is needed.
A final point of discussion is the potential long-term effects of IDO expression. Although we did not observe any malignancies or infectious complications within our IDO gene-treated animals, there is concern that constant IDO expression may lead to a generalized loss of required immune surveillance. Supporting this concern is the recent finding that memory CD8+ T cells are susceptible to tryptophan catabolism mediated by IDO. 44 Overexpression of IDO in vivo attenuated the generation of both central memory CD8+ T cells (Tcm) and effector memory CD8+ T cells (Tem). This observation has both positive and negative implications. Although it suggests that IDO expression in vivo may be able to modulate inhibitor titers in animals or patients with preexisting inhibitors, it also suggests it could attenuate immune responses to infections or transformed cells. This finding may also explain why tumor cells often escape immune recognition as many tumors have been observed to upregulate the expression of IDO. As our understanding of the mechanisms of action of IDO and kynurenine evolves, we may likely be able to manipulate this pathway to both enhance and modulate the immune system.
Materials and methods
Vector construction
Transposons expressing human B-domain-depleted FVIII and human indoleamine 2,3-dioxygenase (hIDO) have been previously described. 3, 30 The hyperactive transposase expression plasmid (pCMV-HSB16) was used in these studies. 45 The ability of these plasmids to express biologically active protein was confirmed in vitro before the animal studies.
Establishment of cell lines overexpressing human IDO
The murine heart endothelial cell line (SMHEC) was manipulated to overexpress IDO as follows: cells (6 cm dishes) were co-transfected with three plasmids, 1.95 mg of pMSZ-CMV-IDO (or pMSZ-CMV-GFP), 0.15 mg of pMSZ-Neo31 and 1 mg of pCMV-HSB16, using GeneJammer transfection reagent from Stratagene (La Jolla, CA, USA). At 2 days after transfection, cells were trypsinized, counted and 3000 cells were plated on 10 cm dishes in medium containing 1 mM G418. Following 14 days of drug selection that included a medium change at day 7, isolated colonies were picked and grown separately. Culture medium and total cell lysates from 24 independent clones were resuspended in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) lysis buffer (20 mM HEPES, 0.5 M NaCl, 1 mM EDTA, 0.25% Triton X-100, 1 mM EGTA supplemented with a protease inhibitor cocktail) and screened for expression of IDO by western blotting and IDO activity assays. 46 As a negative control, cells transfected with the transposon pMSZ-CMV-GFP were used in place of the pMSZ-CMV-IDO and an identical selection process was carried out.
In vivo gene delivery and western blotting
Hemophilia A mice (exon 16 disrupted) were breed and housed under specific-pathogen-free conditions and treated according to the NIH Guidelines for Animal Care and Use of Laboratory Animals with approval of the IACUC of the University of Florida. FVIII-and IDOexpressing transposons were combined with transposase and co-delivered into hemophilic A mice through tail vein by hydrodynamic injection. 47 On the basis of preliminary results, the ideal ratio of FVIII to IDO transposons was 1:1 and the ratio of transposon/ transposase was 10:1. The following amounts of DNA were delivered: 100 mg pMSZ-CMV-FVIII, 100 mg pMSZ-CMV-IDO and 20 mg pCMV-HSB16. The plasmid pcDNA3.1 was used in place of pMSZ-CMV-IDO in the FVIII transposon alone group. The plasmids were diluted in 0.85% saline and the injection volume ranged from 1.8 to 2.0 ml based on the body weight (B10%). Blood samples were collected by tail bleeding from the animals at 3 days, 1 week, 2 weeks, 4 weeks and every 4 weeks thereafter until the end of the experiments (24 weeks). At 3 days and 4 weeks after gene delivery, three mice in each group were euthanized to obtain liver tissue that was analyzed by western blotting to detect IDO and FVIII expression as described previously. 3, 30 FVIII activity assay, Bethesda titers and kynurenine concentrations Detection of biologically active human FVIII in tissue culture supernatants and mouse plasma was measured using the chromogenic Coatest from diaPharma (West Chester, OH, USA) according to our previous publications. 3 Anti-human FVIII inhibitory antibodies were measured using the Bethesda assay. 48, 49 Briefly, equal volumes of plasma from gene-therapy-treated mice IDO modulates inhibitor formation L Liu et al were mixed with pooled normal human plasma. Following incubation at 37 1C for 2 h, the residual FVIII activity of each sample was analyzed using a Coatest. One Bethesda unit per milliliter was defined as the ability of the murine plasma to cause a 50% neutralization of FVIII activity in the pooled human plasma. For samples with high Bethesda titers (44 BU), serial dilutions of the plasma in assay buffer were used to better fit the standard curve. Plasma kynurenine concentrations were determined at the indicated time points according to the methods described previously 30 using purified L-kynurenine (0-1000 mM) as a standard.
Immunohistochemistry
Two weeks after gene delivery, animals (B3-4 mice per group) were euthanized and their livers were perfused with cold phosphate-buffered saline (PBS), fixed in situ, harvested and processed as described previously. 3, 31 Antibodies against the T-cell marker CD3 (Invitrogen Corporation, Carlsbad, CA, USA) were applied to the liver cryosections from each group. Separate slides were also stained with the Red In situ Apoptosis Detection Kit from Chemicon International (Temecula, CA, USA), which uses a rhodamine-conjugated anti-digoxigenin antibody to detect apoptotic cells. At the completion of the experiment (24 weeks), liver cryosections (5 mm) from each group were prepared and stained with antibodies against FVIII (polyclonal, affinity-purified, sheep anti-human FVIII at 1:500 dilution, from Affinity Biologicals Inc., Ancaster, Canada) or IDO (polyclonal, rabbit anti-IDO at 1:500 dilution from Upstate, Charlottesville, VA, USA). Fluorescein-conjugated anti-sheep and Texas-red-conjugated anti-rabbit IgGs were used as secondary antibodies with Hoechst staining of the nuclei. Sections were viewed and photographed with a Spot camera attached to a Nikon Eclipse fluorescent microscope and images were processed using Adobe Photoshop.
Gene integration studies
For insertion site analysis, a splinkerette PCR technique was used to recover sequences flanking transposon insertion at the 3 0 side (right IR/DR element) using a technique previously described. 3, 50 Potential clones were subjected to DNA sequencing to identify sites of integration, and BLAST analysis was performed to determine the chromosomal location.
Isolation of PBMC, co-culture and flow cytometry
PBMCs were isolated by density centrifugation (FicollHypaque; Pharmacia, Uppsala, Sweden). Briefly, citrateanticoagulated blood from five different donor mice was pooled (B4 ml), diluted with an equal volume of serumfree medium and overlaid onto Ficoll. Samples were centrifuged at 400 g for 35 min at 18 1C with slow deceleration. The upper plasma layer was aspirated away, the cell layer (B2 ml) was transferred to fresh 15 ml conical and three volumes of serum-free medium were added. Following gentle inversion to mix, samples were centrifuged at 150 g for 10 min at 18 1C, and the pellet was resuspended in 8 ml cold 1 Â PBS. Following centrifuge at 50 g for 10 min at 18 1C, the cell pellet was resuspended in RPMI medium, counted and the cells were plated in Nunc 25 mm Tissue Culture Inserts (Nalge NUNC International, Rochester, NY, USA)
(1 Â 10 6 cells per well, 0.4 mm pore size). The inserts were placed into six-well dishes that had been previously plated with SMHEC overexpressing IDO or GFP as a control. PHA was added to the PBMCs within the insert at final concentration of 1 mg ml À1 to stimulate lymphocytes proliferation. After 24 h, cells within the insert were counted and lymphocyte apoptosis was analyzed by flow cytometry using the TACS Annexin V-FITC apoptosis detection kit (R&D Systems Inc., Minneapolis, MN, USA) according to the manufacturer's instructions. To elucidate the effects of the tryptophan metabolite kynurenine on lymphocyte proliferation and apoptosis, appropriate amounts of kynurenine were added into the culture medium of control cells to achieve the same concentration as that found in the medium of IDO-expressing SMHEC cells. Experiments were also performed in the presence of the IDO inhibitor, 1-methyltrypophan at 1 mM (1-MT; Sigma-Aldrich, St Louis, MO, USA). Two independent experiments were performed in triplicate, and the data are expressed as the mean plus/ minus the standard error of the mean (mean ± s.e.m.).
Statistical analysis
Animal data are expressed as mean±s.e.m, and statistical analyses were performed using Prism software (GraphPad, San Diego, CA, USA). One-way analysis of variance with the Newman-Keul test was used to evaluate differences between groups. A P-value of o0.05 was considered statistically significant.
